ADAM17 and non-small cell lung carcinoma: A9 (B8), which exhibits cross-reactivity with both human and mouse ADAM17, demonstrates EGFR-TKI-mediated antitumor effects in NSCLC cells, with IC50 values of 0.22 nM for human ADAM17 and 0.25 nM for mouse ADAM17 (Yang et al., 2019).